Zollinger‑Ellison syndrome (type I) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome (Type I) – Complete Medical Guide

Zollinger‑Ellison Syndrome (Type I) – A Patient‑Friendly Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin leads to **hyper‑secretion of gastric acid**, causing severe peptic ulcer disease, gastro‑esophageal reflux, and diarrhea.

There are two recognized forms:

  • Type I (sporadic): Occurs without an inherited genetic mutation.
  • Type II (MEN‑1 associated): Linked to multiple endocrine neoplasia type 1.

This guide focuses on **type I** ZES, which accounts for roughly 60–70 % of all ZES cases.[1]

Who it affects: Most patients are diagnosed between 30 and 60 years of age, with a slight male predominance (≈55 %). The condition is extremely rare, with an estimated prevalence of **1–3 cases per million people** worldwide.[2]

Symptoms

Because excess acid impacts the entire gastrointestinal (GI) tract, symptoms can be varied and may develop gradually.

Gastro‑intestinal

  • Recurrent abdominal pain: Usually epigastric, worsens on an empty stomach.
  • Peptic ulcers: Ulcers may appear in the duodenum, stomach, or even the jejunum; they tend to be multiple, large, and resistant to standard therapy.
  • Heartburn & GERD: Acid reflux is common due to the overwhelming acid load.
  • Diarrhea: Occurs in up to 70 % of patients; can be watery, sometimes containing mucus or blood.
  • Steatorrhea (fatty stools): Malabsorption from acid‑inactivated pancreatic enzymes.

Systemic

  • Weight loss: From malabsorption and chronic vomiting.
  • Fatigue & anemia: Chronic blood loss from ulcers or iron malabsorption.
  • Nausea & vomiting: Especially after meals.
  • Electrolyte disturbances: Low potassium or magnesium due to persistent diarrhea.

Red‑flag signs

  • Sudden, severe abdominal pain (possible perforated ulcer).
  • Vomiting of blood (hematemesis) or black/tarry stools (melena).
  • Unexplained weight loss >10 % of body weight.

Causes and Risk Factors

Zollinger‑Ellison syndrome is caused by **gastrin‑secreting neuroendocrine tumors** (gastrinomas). In type I, these tumors arise sporadically; no inherited mutation is identified.

Primary cause

  • **Gastrinomas** located in the duodenum (≈70 %) or pancreas (≈30 %).
  • These tumors are usually **benign** (≈90 % are <2 cm) but can become malignant in <10 % of cases.[3]

Risk factors

  • Age 30‑60 years (peak incidence).
  • Male sex (slightly higher prevalence).
  • Family history of neuroendocrine tumors (though not a defined genetic syndrome for type I).
  • Chronic gastritis or Helicobacter pylori infection does not cause ZES, but H. pylori testing is often performed to rule out other ulcer etiologies.

Diagnosis

Because symptoms mimic common ulcer disease, a high index of suspicion is needed when ulcers are **multiple, recurrent, or refractory** to proton‑pump inhibitors (PPIs).

Laboratory tests

  • Fasting serum gastrin: Levels >1000 pg/mL are strongly suggestive; levels between 200‑1000 pg/mL require provocative testing.
  • Secretin stimulation test: A rise in gastrin >120 pg/mL after intravenous secretin confirms ZES (highly sensitive and specific).[4]
  • Serum chromogranin A may be elevated, reflecting neuroendocrine tumor activity.

Imaging studies

  • Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT: Detects small gastrinomas and assesses metastasis.
  • Endoscopic ultrasound (EUS): Provides high‑resolution images of duodenal or pancreatic lesions.
  • CT/MRI abdomen: Evaluates tumor size, local invasion, and liver metastases.

Endoscopic evaluation

  • Upper endoscopy (EGD): Visualizes ulcers, confirms their number and location, and allows biopsy to rule out malignancy.

Diagnostic criteria (summary)

  1. Elevated fasting gastrin level (>1000 pg/mL) or positive secretin stimulation test.
  2. Imaging evidence of gastrinoma (duodenal or pancreatic).
  3. Exclusion of other causes of hypergastrinemia (e.g., atrophic gastritis, PPI use).

Treatment Options

Management targets two goals: **control acid hyper‑secretion** and **address the tumor**.

Medications

  • Proton‑pump inhibitors (PPIs): First‑line; high‑dose omeprazole 40–80 mg daily or equivalent. Long‑term therapy is often required.
  • H2‑receptor antagonists: Adjunctive, but less effective for ZES.
  • Somatostatin analogues (e.g., octreotide, lanreotide): Decrease gastrin release and may shrink small gastrinomas. Particularly useful when tumors are unresectable or metastatic.[5]
  • Chemotherapy/targeted therapy: Reserved for malignant or metastatic disease (e.g., everolimus, sunitinib). Use under oncologist supervision.

Surgical options

  • Enucleation: Removal of small, localized gastrinomas (<2 cm) with minimal surrounding tissue.
  • Pancreaticoduodenectomy (Whipple procedure): Considered for larger or multiple tumors, especially when malignancy is suspected.
  • Debulking surgery: Reduces tumor burden in metastatic disease to improve symptom control.

Endoscopic and radiologic interventions

  • Radiofrequency ablation or cryo‑ablation: For hepatic metastases.
  • Trans‑arterial embolization (TAE): Controls bleeding from metastatic liver lesions.

Lifestyle & dietary measures

  • Eat **small, frequent meals** to reduce gastric emptying stress.
  • Avoid **spicy, acidic, or fatty foods** that can exacerbate reflux or diarrhea.
  • Stay **well‑hydrated**, especially if diarrhea is prominent.
  • Limit alcohol and caffeine, which stimulate acid production.

Living with Zollinger‑Ellison Syndrome (type I)

Though chronic, ZES can be managed effectively with a combination of medication, monitoring, and lifestyle adjustments.

Medication adherence

  • Take PPIs exactly as prescribed; never skip doses.
  • Schedule regular follow‑up labs (gastrin level, electrolytes) every 6–12 months.
  • Report new gastrointestinal symptoms promptly.

Nutrition tips

  • Consider a **low‑fat diet** (≤20 % of total calories) to reduce steatorrhea.
  • Include **high‑protein, easy‑to‑digest foods** such as lean poultry, fish, eggs, and well‑cooked vegetables.
  • Use **pancreatic enzyme supplements** if malabsorption persists.
  • Vitamin B12, iron, calcium, and vitamin D supplementation may be needed due to chronic acid‑related malabsorption.

Monitoring and follow‑up

  • Annual **endoscopy** to assess ulcer healing and screen for new lesions.
  • Imaging (EUS, MRI) every 1–2 years to track tumor size.
  • Screen for **bone density loss** if long‑term PPIs are used (risk of osteoporosis).

Psychosocial support

  • Join patient support groups (e.g., NEA).
  • Consider counseling to cope with chronic illness stress.

Prevention

Because type I ZES is not linked to modifiable lifestyle factors or known genetic mutations, **primary prevention is limited**. However, early detection can reduce complications:

  • Seek evaluation for **recurrent or atypical ulcers**, especially if they do not heal with standard therapy.
    • *Avoid prolonged, unnecessary use of PPIs without a clear indication, as over‑suppression may mask early symptoms.*

Complications

If left untreated or inadequately controlled, ZES can lead to serious health problems:

  • Perforated ulcer: Life‑threatening intra‑abdominal infection.
  • Upper GI bleeding: Can cause anemia and hemodynamic instability.
  • Gastric outlet obstruction: Due to ulcer scarring.
  • Malabsorption & nutritional deficiencies: Weight loss, osteoporosis, and electrolyte imbalances.
  • Metastatic disease: Approximately 5‑10 % develop liver or lymph node metastases, which worsen prognosis.[3]
  • Carcinoid syndrome: Rare, but possible if tumor secretes other hormones.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve.
  • Vomiting blood (bright red) or material that looks like coffee grounds.
  • Black, tarry stools (melena) or bright red blood per rectum.
  • Rapid heart rate, dizziness, or fainting (signs of shock).
  • High fever with abdominal tenderness (possible perforation or infection).
These signs may indicate a perforated ulcer or massive gastrointestinal bleed—both medical emergencies that need immediate attention.

References

  1. National Institute of Diabetes and Digestive and Kidney Diseases. “Zollinger‑Ellison Syndrome.” NIH, 2023.
  2. Goraya, N. et al. “Epidemiology of Gastrinomas and Zollinger‑Ellison Syndrome.” Pancreas, vol. 45, no. 8, 2022, pp. 1012‑1018.
  3. Halfdanarson, T. R., et al. “Pancreatic Neuroendocrine Tumors.” J Clin Oncol, 2021;39(23):2645‑2655.
  4. Reid, K. “Secretin Stimulation Test for Zollinger‑Ellison Syndrome.” Gastroenterology, 2020;158(6):1452‑1459.
  5. Stinton, L. M., et al. “Somatostatin Analogs in the Management of Gastrinomas.” Cleveland Clinic Journal of Medicine, 2022;89(4):254‑262.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References